Celgene’s “Buy” Rating Reaffirmed at Deutsche Bank (CELG)
A number of other analysts have also recently weighed in on CELG. Analysts at RBC Capital raised their price target on shares of Celgene from $95.00 to $100.00 in a research note on Wednesday, August 6th. They now have an “outperform” rating on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Celgene in a research note on Monday, July 28th. They now have a $92.00 price target on the stock. Finally, analysts at JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Celgene in a research note on Friday, July 25th. They now have a $95.00 price target on the stock, up previously from $85.00. One analyst has rated the stock with a sell rating, three have given a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $97.00.
Shares of Celgene (NASDAQ:CELG) traded up 2.18% on Tuesday, hitting $95.435. The stock had a trading volume of 2,667,249 shares. Celgene has a 1-year low of $66.85 and a 1-year high of $93.86. The stock’s 50-day moving average is $87.87 and its 200-day moving average is $79.89. The company has a market cap of $76.301 billion and a price-to-earnings ratio of 53.99.
Celgene (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, July 24th. The company reported $0.90 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.89 by $0.01. The company had revenue of $1.87 billion for the quarter, compared to the consensus estimate of $1.85 billion. During the same quarter last year, the company posted $1.52 earnings per share. Celgene’s revenue was up 17.1% compared to the same quarter last year. Analysts expect that Celgene will post $3.67 EPS for the current fiscal year.
Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.
Receive News & Ratings for Celgene Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Co and related companies with Analyst Ratings Network's FREE daily email newsletter.